High virological failure rates in HIV-1 perinatally infected children in South Africa: A retrospective cohort study by Makatini, Z N et al.
255       March 2021, Vol. 111, No. 3
RESEARCH
The rapid scale-up of global HIV antiretroviral therapy (ART) in 
resource-limited settings has resulted in the successful enrolment 
of millions of HIV-infected children into care and treatment 
programmes.[1] South Africa (SA) has made great strides in HIV 
treatment, and has the largest ART programme in the world, with 
~4.4 million people receiving ART.[2]
The scale-up of ART has resulted in improvements in virological 
and immunological parameters, as well as reductions in mortality, 
morbidity and comorbidities.[3,4] However, viral load rebound may 
still occur in some patients, despite an initial good response to ART. 
Maintenance of maximal and durable suppression of plasma viraemia 
has been particularly challenging for HIV-infected children, and non-
adherence is often the strongest predictor of failure to achieve viral 
suppression.[5-7] The challenges that limit high adherence in children 
include complex ART regimens, significant side-effects, limited 
availability of paediatric formulations, the lifelong duration ART, 
and dependence on a caregiver to administer the medication.[8-10] 
A systematic review of resistance data in children from developing 
world settings found that 90% of those failing first-line regimens had 
at least one detectable resistance mutation.[11] Virological failure rates 
of up to 50% have been reported in African children during the 12 - 
24 months after ART initiation.[12-14]
Studies that include long-term follow-up of children on 
combination ART (cART) are limited; it is therefore difficult to 
generate reliable estimates of the incidence of first-line failure in large 
paediatric cohorts in public sector settings and to identify the factors 
associated with virological failure. We therefore analysed data from 
a large cohort of HIV-positive children and adolescents receiving 
care in one of the largest public sector ART programmes in SA to 
estimate the cumulative incidence of virological failure, identify the 




A retrospective cohort study of HIV-1 perinatally infected children 
was conducted at the Dr George Mukhari Academic Hospital 
(DGMAH) in Pretoria, SA. Patients included in the study were 
aged <17 years, initiated first-line ART between 1 January 2004 
and 31 December 2013, and had at least 5 years of HIV viral load 
measurements. Longitudinal clinical and demographic data were 
collected from the clinical files until last follow-up review or up 
to a 5-year time point following the initiation of ART. Failure to 
achieve an HIV viral load below the limit of detection was assessed at 
multiple time points during a 5-year period. For the purposes of this 
study, virological failure was defined as a viral load of >1 000 copies/
mL 1 year after ART initiation.
HIV drug resistance
HIV genotyping was performed using an in-house drug resistance 
assay. Briefly, a 1.7 kb amplicon was generated by reverse transcriptase 
(RT)-initiated polymerase chain reaction of the entire protease 
(PR) and partial RT-coding regions. The amplicon was sequenced 
using five primers and included codons 1 - 99 of PR and codons 
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1 - 230 of RT. Sequencing was performed with either an ABI PRISM 
3730 Genetic Analyzer or an ABI PRISM 3100-Avant Genetic 
Analyzer (Applied Biosystems, USA). To identify drug resistance 
mutations and predict drug susceptibility, the Stanford HIV Drug 
Resistance Database version 8.3 (Stanford University, USA) was 
utilised. Susceptibility to boosted lopinavir (LPV), atazanavir and 
darunavir was determined using the penalty score where, from the 
total score for each of the three protease inhibitors (PIs), five levels 
of inferred drug resistance were reported as susceptible, potential 
low-level resistance, low-level resistance, intermediate resistance and 
high-level resistance.
Statistical analysis
Descriptive statistics were used to summarise continuous variables 
and counts, while percentages were used for categorical variables. 
The Kaplan-Meier method was used to estimate virological failure 
at different time points. The incidence of virological failure was 
calculated in person-years of observation. Univariate and multivariate 
logistic regression analyses were used to examine the relationships of 
independent variables with the primary outcomes. All variables were 
included in the multivariate analysis model with logistic regression 
using the enter model, and multivariate odds ratios (ORs) and 
respective 95% confidence intervals (CIs) were obtained. Variables 
with a p-value <0.05 and an adjusted hazard ratio with a 95% CI on 
the final model of multivariate logistic regression were considered 
statistically significant predictors of virological failure. The Cox 
proportional hazards model was used to identify factors associated 
with virological failure. Statistical tests were based on a two-
sided significance, and a p-value ≤0.05 was considered statistically 
significant. All statistical analyses were performed using SAS 9.1 
software (SAS Institute, USA).
Ethical considerations
Sefako Makgatho Health Sciences University approved collection 
of clinical and HIV drug resistance data (ref. no. SMUREC/
M/30/2017:PG). To protect patient confidentiality, all records were 
anonymised and deidentified prior to analysis.
Results
Of 2 234 HIV-positive perinatally infected children initiated on ART 
from 2004 to 2013, 210 children with HIV monitoring data missing 
from medical files were excluded. An additional 365 children who 
had <5 HIV viral load measurements at the time of study recruitment 
were also excluded, yielding 1 659 records for analysis (Fig. 1).
Baseline characteristics
Of the initial cohort of 2 024 children, 1 033 (51.0%) were male and 
1 255 (62.0%) were aged <5 years, with 300 (23.9%) being <1 year 
of age. Seventy-six percent of the children presented with World 
Health Organization (WHO) stage III/IV disease, with a median 
(interquartile range (IQR)) nadir CD4% of 13.3 (7.23 - 21) and a 
median (IQR) baseline HIV viral load of 5.3 (4.5 - 5.8) log10 copies/
mL. The median (IQR) duration on cART for the entire study 
population was 5 (2 - 7) years. Baseline and clinical characteristics are 
summarised in Tables 1 and 2.
First-line regimen
Children who initiated ART from 2004 to 2010 were placed on 
stavudine + lamivudine (d4T + 3TC), while those who initiated 
ART after 2010 received an abacavir (ABC) + 3TC-based nucleoside 
reverse transcriptase inhibitor (NRTI) backbone. Over half of the 
children <3 years of age were initiated on LPV/ritonavir (LPV/r) + 
2 NRTIs (51.8%; 488/941). Despite the SA guidelines being followed, 
41.8% of the children (393/941) were initiated on an efavirenz 
(EFV)-based regimen. The remaining children were on nevirapine 
(NVP) (n=48; 5.1%) and ritonavir (RTV) (n=12; 1.27%). Of children 
≥3 years of age, 797 (73.6%) initiated ART consisting of a non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen – 
763 (70.5%) on EFV and 9 (0.8%) on NVP.
An RTV-boosted PI (LPV/r) accounted for 38.7% (784/2 024) 
of the PI regimens prescribed. The proportion of patients on a 
PI regimen varied according to age categories: 62.2% (n=488) for 
those aged <3 years, 7.9% (n=62) for those aged 3 - 5 years, 21.7% 
(n=170) for those aged 6 - 10 years, and 8.2% (n=64) for those aged 
11 - 16 years.
Children initiated on cART 
between 2004 and 2013,
N=2 234 
Children with missing 
data excluded,
n=210 (9.4%)




Children with <5 years'




analysis of virological failure,
n=1 659
Fig. 1. Flow diagram of the medical files selected for virological failure 
analysis. (cART = combination antiretroviral therapy.)





Male 1 033 (51.0)
Age (years)
<1 300 (14.8)
1.1 - 5 955 (47.2)
5.1 - 10 576 (28.5)
10.1 - 15 190 (9.4)
15.1 - 17 3 (0.1)
Maternal status
Alive 1 423 (70.3)
Deceased 601 (29.7)
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Incidence of virological failure
A total of 1 659 children were observed for 7 075 PYFU; of these, 
425 (25.6%) experienced virological failure by 1 year post ART 
initiation. The incidence of virological failure after first-line ART 
among the children tested was 18.5 per 100 PYFU. The rates of 
virological failure at different time periods are shown in Fig. 2.
Twenty-five children (5.9%) had persistent viraemia with no 
evidence of viral suppression at each successive year up to 5 years. 
Despite the observed virological failure pattern, high levels of viral 
suppression were achieved by a large proportion of children, with 
74% of the cohort achieving viral suppression at the 12-month visit, 
1 378 (83%) at 2 years, 1 410 (85%) at 3 years, 1 475 (89%) at 4 years, 
and 1 485 (89%) at 5 years. The cumulative hazard of virological 
failure at 1 to 5 years post ART initiation was 12%, 20%, 27%, 32% 
and 36%, respectively.
Predictors of virological failure
Table 3 summarises univariate and multivariate risk factors associa-
ted with virological failure in HIV perinatally infected children. In 
univariate analysis, the nadir CD4% was the only variable statistically 
significantly associated with virological failure (p=0.042).
Male gender, age, concurrent tuberculosis (TB) treatment, and 
mother having died by the time the child presented, were independently 
associated with virological failure. Gender at 24 months post ART 
initiation was statistically significant, with increased odds of a male 
child having virological failure (OR 1.440, 95% CI 1.074 - 1.930; 
p<0.015). Additionally, concurrent TB treatment at ART initiation 
(p=0.0042), age (OR 1.066, 95% CI 1.026 - 1.109; p<0.001), and 
mother having died before ART initiation (OR 1.475, 95% CI 1.005 - 
2.164; p<0.047) were found to be predictive of virological failure.
HIV drug resistance
Over the 5-year follow-up period, 337 children (20.3%) had plasma 
submitted for HIV resistance testing; of these samples, 17 failed 
to amplify. Of the remaining 320 samples, 71 (22.1%) displayed 
wild-type virus, while 249 (77.8%) had at least one drug resistance 
mutation. NNRTI resistance mutations were observed in 162/249 
(65.1%), with 158/249 (63.4%) displaying dual-class NNRTI/NRTI 
resistance. The M184V mutation was present in 237 children (95.1%), 
and thymidine analogue mutations (TAMs) in 125 (43.8%). Among 
TAMs, the prevalence was 32% for D67N, 22.4% for K70R, 20% 
for K219Q/E/N, 32% for M41L, 14.4% for T215F/Y and 2.4% for 
L210W. The most common NNRTI mutations were K103N (n=92; 
46.2%), V106M (n=61; 30.6%), Y181C (n=37; 18.6%), and G190A 
(n=37; 18.6%). Of the 94 children on a PI-based regimen at the time 
of genotyping (32.9%), 10.5% (30/285) harboured major protease 
mutations. Fifteen children displayed a K65R resistance mutation, 
with 7 records of children (46.6%) having no documented exposure 
to tenofovir.
Discussion
This study assessed virological failure in a large HIV paediatric 
cohort in a public sector setting in SA where routine viral load 
monitoring is available. Of HIV-infected children, 425 (26%) met the 
definition of virological failure at 1 year post ART initiation. Overall, 
the incidence rate of virological failure was 18.5 per 100 PFYU, and 










0 - 9 455 (22.5)
10 - 15 395 (19.5)




d4T, 3TC, EFV 548 (27.1)
d4T, 3TC, NVP 47 (2.3)
d4T, 3TC, LPV/r 211 (10.4)
d4T, 3TC, RTV 8 (0.4)
AZT, 3TC, EFV 140 (6.9)
AZT, 3TC, NVP 33 (1.6)
AZT, 3TC, LPV/r 88 (4.3)
AZT, 3TC, RTV 5 (0.2)
ABC, 3TC, EFV 465 (23.0)
ABC, 3TC, NVP 4 (0.2)
ABC, 3TC, LPV/r 472 (23.3)
ABC, 3TC, RTV 0
AZT, ddI, LPV/r 1 (0.04)
ABC, ddI, LPV/r 1 (0.04)
AZT, EFV, NVP 1 (0.04)












No 1 405 (69.4) 
WHO = World Health Organization; d4T = stavudine; 3TC = lamivudine;  
EFV = efavirenz; NVP = nevirapine; LPV/r = lopinavir/ritonavir; RTV = ritonavir;  
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Cumulative virological failure                        No failure
Fig. 2. Virological failure at different time periods.
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the 5-year cumulative incidence of failing on a first-line regimen was 36%. These 
findings are higher than virological failure rates of 6 - 16%[15-18] reported in other 
SA settings, although virological failure rates of 20%[19] and 26%[20] in Thai and 
Ugandan children, respectively, are consistent with our findings. With children 
reported to be at higher risk of virological failure than adults,[21] much higher rates 
have been reported in clinical programmes in Kenya, Mali and Cote d’Ivoire.[22-24] 
Of note, with different viral load cut-off points and varying follow-up periods in 
different studies, a direct comparison of virological failure rates is difficult. While 
a relatively high proportion of children with virological suppression on ART is 
reassuring, the current failure rates fall short of the goals of achieving 90% viral 
suppression by 2020 for those on ART.
Of particular concern are the 25 children (5.9%) with persistent viraemia at 
each successive year for up to 5 years. However, these figures are much lower 
than the reported persistent viraemia of 57% reported by Davies et al.[25] in a 
similar cohort. Clinicians’ non-adherence to protocols for switching to second-
line ART is a challenge that has been reported in the SA public setting, and such 
delays lead to the emergence of HIV drug resistance, compromising subsequent 
regimens.[26-29]
In the present study, children with a low nadir CD4%, male gender, concurrent 
TB treatment and maternal death were at increased risk of virological failure, 
highlighting a need to intensify adherence counselling in such population 
groups. The association of virological failure with low nadir CD4%, male 
gender, concurrent TB treatment and the death of a mother has been described 
previously.[30-38]
Our finding of a prevalence of HIV drug resistance of 78% corroborates reports 
of high proportions of children with emergence of HIV drug resistance mutations 
in SA.[13,16,39-41] The high prevalence of HIV drug resistance in our cohort was 
largely driven by resistance to NNRTIs, with 62% of children on EFV at the time 
of genotyping. Among NRTIs, the most prevalent HIV drug resistance mutations 
were M184V and TAMs, reflecting the extensive use of d4T or AZT and 3TC 
as part of the first-line regimen prior to the replacement of d4T with ABC. The 
proportion of wild-type virus (22.1%) was consistent with other studies reporting 
between 9%[15] and 22%,[40] highlighting non-adherence issues.
Study strengths and limitations
This study has several strengths, including the relatively large sample size and 
a high number of children initiated from 2004 to 2013. Paediatric resistance 
data were also drawn from an HIV clinic with real-time viral load monitoring. 
Nonetheless, the DGMAH clinic is a tertiary centre serving a semi-urban 
population and may not be representative of HIV public sector paediatric 
clinics across all of SA. Moreover, antiretroviral medications administered for 
the prevention of mother-to-child transmission were not consistently recorded 
in all the patient files. The impact of different antiretroviral agents on HIV 
transmission resistance and the development of drug resistance could therefore 
not be examined. Other limitations were the lack of documentation of adherence 
activity, use of traditional medications, and paediatric national ART guidelines 
influencing regimen changing over the study period.
Conclusions
Virological failure and emergence of HIV drug resistance remain major 
challenges for paediatric ART management in this SA healthcare setting.
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